A Prospective Multi-Centre Registry of EvroSure (Everolimus Drug Eluting CoCr Coronary Stent) to Investigate Safety and Effectiveness Name of Study: EverGreen
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 888
- 试验地点
- 5
- 主要终点
- 888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days
研究概览
简要总结
History of Device Development and Study Rationale:
Drug-eluting stents (DES) revolutionized percutaneous coronary intervention (PCI) by significantly reducing restenosis and the need for repeat procedures compared to bare-metal stents (BMS). Introduced in the early 2000s, DES quickly became the standard of care due to its superior antiproliferative properties.
DES consists of a metal stent, an antiproliferative drug, and a polymer coating. The stent provides structural support while the drug is gradually released to inhibit tissue growth within the artery. This dual action effectively prevents restenosis, a common complication after PCI.
Contemporary guidelines strongly recommend DES over BMS for various clinical scenarios. The proven efficacy and safety of current-generation DES make them the preferred treatment option for patients undergoing PCI.
First-generation drug-eluting stents:
First-generation drug-eluting stents (DES) marked a significant advancement in interventional cardiology, addressing the persistent issue of in-stent restenosis (ISR) associated with bare-metal stents (BMS). These innovative devices, composed of a metal frame, an antiproliferative drug (sirolimus or paclitaxel), and a polymer coating, were designed to release the drug gradually, preventing tissue growth within the artery. Clinical trials demonstrated the superior efficacy of DES over BMS in reducing ISR and target lesion revascularization (TLR). The RAVEL trial, for example, found a dramatic decrease in ISR with sirolimus-eluting stents (SES). Subsequent studies and meta-analysis confirmed the benefits of both SES and paclitaxel-eluting stents (PES) compared to BMS, particularly in high-risk patients.
The introduction of DES represented a paradigm shift in interventional cardiology, offering a more effective and durable solution for patients with coronary artery disease.
Second-generation drug-eluting stents:
Second-generation drug-eluting stents (DES) were developed to address the safety concerns associated with first-generation DES, such as stent thrombosis (ST), incomplete endothelialization, and polymer-induced inflammation. These newer stents incorporate less toxic drugs, more biocompatible coatings, and thinner, more flexible struts. Clinical trials have demonstrated the superior safety and efficacy of second-generation DES compared to their predecessors. Studies comparing everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) to first-generation DES have shown significant reductions in ST, myocardial infarction (MI), and target lesion revascularisation (TLR). Head-to-head comparisons of EES and ZES have also revealed comparable outcomes in real-world patient populations. Both stents are effective and safe for the treatment of obstructive coronary artery disease, making them the preferred choice for percutaneous coronary intervention.
Study Rationale:
The introduction of drug-eluting stents (DES) marked a significant leap in interventional cardiology by addressing the limitations of bare-metal stents (BMS), primarily through reducing restenosis and the need for repeat procedures. First-generation DES, equipped with antiproliferative drugs like sirolimus and paclitaxel, demonstrated superior efficacy in preventing in-stent restenosis. However, safety concerns, including stent thrombosis and polymer-induced inflammation, led to the development of second-generation DES, which utilizes more biocompatible materials and refined designs. Clinical trials have consistently shown that these newer DES offer enhanced safety and effectiveness, solidifying their position as the preferred treatment option in percutaneous coronary interventions.
Study Objectives
The main objective of this study is to assess the safety and effectiveness of the EvroSure Everolimus Drug eluting CoCr stent in obstructive coronary artery disease.
Primary Objective
The primary endpoint of this study is to monitor Major Adverse Cardiac Events (MACE) at 30 days.
Secondary Objective
The following secondary effectiveness endpoints are as follows:
- Angiographic/device success (%)
- Procedural success (%)
- Clinically justified Target Lesion Revascularization (TLR) (%) at 12 months
The following secondary safety endpoints are:
- MACE (%) until 12 months (Clinically Justified)
- Device-related SAEs until 12 months (Clinically Justified)
Note: MACE rate is defined as the incidence of the combined clinical endpoint: Composite of Death (Cardiac death as well as Non-Cardiac), Myocardial Infarction (Q-wave and non-Q-wave), Emergency Coronary Artery Bypass Graft Surgery, clinically justified TLR following index procedure.
详细描述
Study Objectives The main objective of this study is to assess the safety and effectiveness of the EvroSure Everolimus Drug eluting CoCr stent in obstructive coronary artery disease.
Primary Objective The primary endpoint of this study is to monitor Major Adverse Cardiac Events (MACE) at 30 days.
Secondary Objective
The following secondary effectiveness endpoints are as follows:
- Angiographic/device success (%)
- Procedural success (%)
- Clinically justified Target Lesion Revascularization (TLR) (%) at 12 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient must be ≥ 18 years of age;
- •Patient was an acceptable candidate for PTCA, Stenting, or Emergent CABG;
- •Patient has clinical evidence of ischemic heart disease or a positive functional study
- •Patient and his or her treating physician agree that the patient will comply with all the required post-procedure follow-up.
- •Target lesion(s) present with ≥50% stenosis, in one or more vessels
- •Target lesions have to be de novo;
- •One or more target lesions require treatment
- •Reference vessel diameter of target lesion(s) must be ≥ 2.25mm and ≤ 4.5mm, by visual estimate
排除标准
- •Previous PTCA with any stent
- •History of CVA or TIA within the last 3 months
- •Patient has active infection
- •Concurrent medical condition with a life expectancy of less than 12 months
- •Clinically relevant contraindication to aspirin, heparin, clopidogrel bisulphate, or ticlopidine including thrombocytopenia, neutropenia, or leukopenia
- •Active peptic ulcer or upper gastrointestinal bleeding.
- •Current participation in an investigational drug or device trial that has not completed its primary endpoint follow-up period.
- •Pregnancy or woman of childbearing potential who, in the opinion of the investigator, does not take adequate measures to prevent conception.
- •Known hypersensitivity or contraindication to cobalt, chromium, or nickel
研究组 & 干预措施
Single Arm
Its a single arm multicenter registry to investigate safety and efficacy of product by clinical follow up at one month and 12 month
干预措施: Drug Eluting Coronary Stent (Device)
结局指标
主要结局
888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days
时间窗: 30 days
The primary endpoint of the study is defined as Major Adverse Cardiac Events (MACE) at 30 days. Note: MACE rate is defined as the incidence of the combined clinical endpoint: Composite of Death (Cardiac death as well as Non-Cardiac), Myocardial Infarction (Q-wave and non-Q-wave), Emergency Coronary Artery Bypass Graft Surgery, clinically justified TLR within 30 days following index procedure.
次要结局
- • MACE (%) Until 12 Months • Device-related SAEs Until 12 Months(12 month)